| ORIGINAL ARTICLE |
|
| Year : 2022 | Volume
: 13
| Issue : 2 | Page : 71-75 |
|
|
Imatinib-induced cardiotoxicity: A study to evaluate cardiac functions in patients on imatinib therapy for chronic myeloid leukemia
P Sanjay Chakravarthy, Pushpa Kumari, Dipendra Kumar Gupta, Mithu Bhowmick, M Devendra Naik, Gudimetla Priyanka
Department of Medicine, VMMC and Safdarjung Hospital, New Delhi, India
Correspondence Address:
Dr. Pushpa Kumari
Department of Medicine, VMMC and Safdarjung Hospital, New Delhi
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/joah.joah_9_21
|
|
|
INTRODUCTION: The success of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia (CML) has increased the focus on survivorship and late toxicity in oncological care. Cardiovascular (CV) health has emerged as an important consideration in patients of CML. Some studies have shown an increased incidence of CHF with Imatinib therapy. This study was conducted to assess the cardiac functions in patients of CML on Imatinib therapy.
METHODS: Seventy newly diagnosed CML patients started on Imatinib therapy having normal baseline cardiac functions as assessed by two-dimensional echocardiography and multigated acquisition (MUGA) scan were included in the study. Further assessment of cardiac functions at 3, 6, and 12 months was done by MUGA scan.
RESULTS: At 3, 6, and 12 months of follow-up, 7.14%, 10%, and 11.43% of patients, respectively, showed evidence of cardiotoxicity in the form of reduced ejection fraction and wall abnormalities on MUGA scan (P = 0.58, 0.013, and 0.006, respectively).
CONCLUSION: Cardiac dysfunction was seen in 11.43% of patients on Imatinib therapy for CML, though none of them were symptomatic. CML patients on Imatinib therapy must be monitored for cardiac functions, especially if they have other CV risk factors.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
